ArticleCell host & microbe2018
Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane.
Article in Cell host & microbe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Visualized analysis of core themes and emerging frontiers in global chikungunya virus studies.Frontiers in microbiology · 2025Pooled it
- Epidemiological and molecular analysis of the Chikungunya virus outbreak in the state of Rondônia.Infection · 2026Review
- Overview of Chikungunya Virus Pathogenesis, Genome Variation, Epidemiology, and Control.Virus research · 2026Review
- Structural elucidation of a unique binding mode by an intact alphavirus human IgG molecule to a quaternary epitope.Nature communications · 2025Article
- Article
- Virus infection and vesicle trafficking.Frontiers in immunology · 2025Review
- Visualizing the virus world inside the cell by cryo-electron tomography.Journal of virology · 2024Review
- Pathogenicity and virulence of chikungunya virus.Virulence · 2024Review
- Antibody-mediated control mechanisms of viral infections.Immunological reviews · 2024Review
- Article
- Missing Wedge Completion via Unsupervised Learning with Coordinate Networks.International journal of molecular sciences · 2024Article
- Missing Wedge Completion via Unsupervised Learning with Coordinate Networks.bioRxiv : the preprint server for biology · 2024Article
- Antibody inhibition of influenza A virus assembly and release.Journal of virology · 2024Article
- The advent of preventive high-resolution structural histopathology by artificial-intelligence-powered cryogenic electron tomography.Frontiers in molecular biosciences · 2024Review
- Article
- Machine learning for cross-scale microscopy of viruses.Cell reports methods · 2023Review
- Multiple Factors Involved in Bone Damage Caused by Chikungunya Virus Infection.International journal of molecular sciences · 2023Review
- A molecular understanding of alphavirus entry and antibody protection.Nature reviews. Microbiology · 2023Review
- Spatiotemporal dynamics and recurrence of chikungunya virus in Brazil: an epidemiological study.The Lancet. Microbe · 2023Article
- Structural constraints link differences in neutralization potency of human anti-Eastern equine encephalitis virus monoclonal antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
Abstract
Neutralizing antibodies (NAbs) are traditionally thought to inhibit virus infection by preventing virion entry into target cells. In addition, antibodies can engage Fc receptors (FcRs) on immune cells to activate antiviral responses. We describe a mechanism by which NAbs inhibit chikungunya virus (CHIKV), the most common alphavirus infecting humans, by preventing virus budding from infected human cells and activating IgG-specific Fcγ receptors. NAbs bind to CHIKV glycoproteins on the infected cell surface and induce glycoprotein coalescence, preventing budding of nascent virions and leaving structurally heterogeneous nucleocapsids arrested in the cytosol. Furthermore, NAbs induce clustering of CHIKV replication spherules at sites of budding blockage. Functionally, these densely packed glycoprotein-NAb complexes on infected cells activate Fcγ receptors, inducing a strong, antibody-dependent, cell-mediated cytotoxicity response from immune effector cells. Our findings describe a triply functional antiviral pathway for NAbs that might be broadly applicable across virus-host systems, suggesting avenues for therapeutic innovation through antibody design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.